FDA grants breakthrough therapy designation for PADCEV plus KEYTRUDA
The combination of PADCEV and KEYTRUDA is indicated as treatment for unresectable metastatic urothelial cancer in patients
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Feb 20
The combination of PADCEV and KEYTRUDA is indicated as treatment for unresectable metastatic urothelial cancer in patients
20 Feb 20
Tecentriq is an initial monotherapy for patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC)
19 Feb 20
About 70% of the antibiotics used globally are administered to farm animals, such as cattle, swine and poultry
19 Feb 20
WuXi Vaccines is a joint venture vaccine Contract Development and Manufacturing Organization (CDMO) between WuXi Biologics and Shanghai…
19 Feb 20
VYNDAQEL is the only EC-approved medicine to reduce mortality and frequency of cardiovascular-related hospitalizations in adults with hereditary…
Pheno Therapeutics will investigate new multiple sclerosis treatments using technology and expertise from the University of Edinburgh
The study in Finland builds on work of the GDNF drug, which has shown promise in restoring damaged…
18 Feb 20
The EC approval is supported by the results from the Phase III HAWK and HARRIER clinical trials, in…
18 Feb 20
The FDA approval provides OTC access to the Voltaren Arthritis Pain, which has been available only with a…
17 Feb 20
The regulatory approval indicated Tecentriq plus chemotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in…